Immune-Shielded, Ultrasound-Stimulated Contrast Agents for Molecular Imaging

用于分子成像的免疫屏蔽、超声刺激造影剂

• 批准号: 7565682
• 负责人: Mark Andrew Borden
• 金额: $ 37.16万
• 依托单位: COLUMBIA UNIV NEW YORK MORNINGSIDE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7565682
• 关键词: Acoustics; Adhesions; Animals; Architecture; Area; Binding; Biology; Biomedical Engineering; Blood; Blood Circulation; Blood Vessels; Book Chapters; Chemical Engineering; Chemicals; Clinic; Clinical; Clinical Medicine; Collaborations; Communities; Complement Activation; Contrast Media; DNA Sequence; Data; Detection; Development; Devices; Diagnosis; Disease; Engineering; Evaluation; Event; Exhibits; Exposure to; Focused Ultrasound Therapy; Fostering; Genome; Goals; Head; Image; Imaging Techniques; Imaging technology; Immune; Immune response; Immune system; In Vitro; Inflammation; Inflammatory; Joints; Leadership; Length; Ligands; Location; Malignant Neoplasms; Manufacturer Name; Manuscripts; Maps; Measures; Microbubbles; Modification; Molecular Profiling; North Carolina; Peptides; Performance; Physiologic pulse; Polymers; Process; Property; Public Health; Pulse taking; Qualifying; Radiation; Reaction; Recording of previous events; Relative (related person); Research; Resolution; Resources; Rodent Model; Safety; Scanning; Site; Small Animal Imaging Systems; Specificity; Surface; System; Technology; Testing; Thrombus; Time; Transducers; Translating; Ultrasonic Transducer; Ultrasonography; Universities; Work; angiogenesis; base; biological research; chemical synthesis; clinical Diagnosis; clinically relevant; concept; cost; design; experience; immunogenic; immunogenicity; improved; in vivo; molecular imaging; new technology; portability; pre-clinical; prevent; research study; tool; two-dimensional

DESCRIPTION (provided by applicant): Many promising studies indicate that molecular imaging with ultrasound can rapidly and economically provide sensitive, high-resolution detection of vascular events, such as angiogenesis, inflammation and thrombus. Thus, Ultrasound molecular imaging has the potential to have a widespread impact in clinical medicine and biological research. Current non-contrast-assisted ultrasound lacks the specificity to detect molecular signatures of targeted disease events, such as angiogenesis. However, ultrasound has the advantages of low cost, portability, and dynamic imaging capability, and is already widely used for clinical diagnosis. Targeted contrast agents have been developed for ultrasound molecular imaging, but their immunogenic properties make them untranslatable to the clinic. Thus, improving the safety and enhancing the sensitivity of ultrasound molecular imaging will have a significant impact on the diagnosis and assessment of thrombus, inflammation, and cancer. Before ultrasound molecular imaging can be translated to the clinic, the immunogenic effects caused by the exposure of targeting ligands on the contrast agent surface must be reduced. We propose research studies to examine in detail the physicochemical mechanisms of immune response to ultrasound contrast agents, and we will use this data to design contrast agents which are shielded from this immune response. Simultaneously, we will study the ultrasound interaction with stealth agents that have been shown in preliminary data to be selectively activated by ultrasound radiation force. Collaboration with an ultrasound device manufacturer will allow the modification of a small-animal imaging system for specific optimization to work with the new stealth contrast agents for enhanced pre-clinical imaging. The end goal will be to develop safer ultrasound contrast agents which will also exhibit increased specificity and circulation time in-vivo, and to improve ultrasound scanner technology to take advantage of new, stealth contrast agents. PUBLIC HEALTH RELEVANCE: Ultrasound molecular imaging has the potential to have a widespread impact in clinical medicine and biological research. Before ultrasound molecular imaging can be translated to the clinic, the immunogenic effects caused by the exposure of targeting ligands on the contrast agent surface must be reduced. The project will develop safer targeted ultrasound contrast agents with decreased immunogenicity and increased specificity in vivo and improve ultrasound scanner technology to take advantage of the new contrast agents.

描述（由申请人提供）：许多有前景的研究表明，超声分子成像可以快速经济地提供血管事件（如血管生成、炎症和血栓）的灵敏、高分辨率检测。因此，超声分子成像技术在临床医学和生物学研究中具有广泛的应用前景。目前的非造影剂辅助超声缺乏检测靶向疾病事件（如血管生成）的分子特征的特异性。然而，超声具有成本低、便携性和动态成像能力的优点，并且已经广泛用于临床诊断。靶向造影剂已被开发用于超声分子成像，但其免疫原性使其无法应用于临床。因此，提高超声分子成像的安全性和灵敏度将对血栓、炎症和癌症的诊断和评估产生重大影响。在超声分子成像技术应用于临床之前，必须降低造影剂表面靶向配体暴露所引起的免疫原性效应。我们提出的研究研究，详细检查的物理化学机制的免疫反应超声造影剂，我们将使用这些数据来设计造影剂屏蔽这种免疫反应。同时，我们将研究超声与隐形剂的相互作用，这些隐形剂在初步数据中已被显示为被超声辐射力选择性地激活。与超声设备制造商的合作将允许修改小动物成像系统，以进行特定的优化，从而与新的隐形造影剂一起工作，以增强临床前成像。最终目标将是开发更安全的超声造影剂，其也将表现出更高的特异性和体内循环时间，并改进超声扫描仪技术以利用新的隐形造影剂。公共卫生相关性：超声分子成像有可能在临床医学和生物学研究中产生广泛的影响。在超声分子成像技术应用于临床之前，必须降低造影剂表面靶向配体暴露所引起的免疫原性效应。该项目将开发更安全的靶向超声造影剂，降低免疫原性，提高体内特异性，并改进超声扫描仪技术，以利用新的造影剂。